Study met both primary endpoints in patients with ER+/HER2- advanced or mBC
Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC
Elacestrant extended PFS in the overall population and the ESR1 mutation subgroup
Plans for regulatory submissions in both the United States and Europe in 2022
Data planned to be presented at the San Antonio Breast Cancer Symposium in December, 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.